"MAPping" the course of chemoprevention in breast cancer

New England Journal of Medicine

Volumn 364, Issue 25, 2011, Pages 2463-2464

  Davidson, Nancy E ^a   Kensler, Thomas W ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RISK; CHEMOPROPHYLAXIS; DRUG CHOICE; DRUG EFFICACY; EDITORIAL; ENDOMETRIUM CANCER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK REDUCTION; VENOUS THROMBOEMBOLISM;

EID: 79959478968     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1106052     Document Type: Editorial

References (10)

1. Davidson NE. Tamoxifen - panacea or Pandora's box? N Engl J Med 1992;326:885-6.
2. Visvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-58.
3. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696-706.
4. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-96.
5. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-18.
6. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
7. Kelloff GJ, Lieberman R, Steele VE, et al. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 2001;57:Suppl 1:46-51.
8. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011 May 9 (Epub ahead of print).
9. Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011 May 2 (Epub ahead of print).
10. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685-92.